Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

BMB. 2021; 6(3): 0-0


Which Markers Playing a Role in Diabetic Polyneuropathy and Neuropathic Pain? (Diyabetik Polinöropati ve Nöropatik Ağrıda Hangi Belirteçler Rol Oynuyor?)

Mehlika Panpalli Ates, Sevgi Ferik, Hayat Guven, Selim Selcuk Comoglu.




Abstract

Öz
Amaç: Diabetes mellitus (DM) hastalarında nöropati ve ağrı gelişiminde ürik asit (UA), C-reaktif protein (CRP), γ-glutamiltransferaz (GGT), eritrosit sedimantasyon hızı (ESH) ve fibrinojen seviyelerinin artışı, inflamasyon ve vasküler hasara bağlı mekanizmalar yoluyla oksidatif stresi artırarak nöropati gelişiminde rol oynayabilir. Bu çalışmada polinöropati (PNP) olan ve olmayan tip 2 DM'li hastalarda serum UA, GGT, CRP, ESR ve fibrinojen düzeylerini karşılaştırmayı amaçladık.
Yöntem ve Gereçler: Çalışmaya toplam doksan altı tip 2 DM hastası ve yirmi dört kişi (kontrol grubu) dahil edildi. Fizik muayeneler, nöropatik ağrı ölçekleri, laboratuvar testleri (UA, GGT, CRP, ESR ve fibrinojen seviyeleri) ve elektronöromiyografi (ENMG) değerlendirildi.
Bulgular: Doksan altı tip 2 DM hastası ve yirmi dört sağlıklı kişi kontrol grubu olarak çalışmaya alındı. Nöropatik ağrısı olan diyabetik polinöropati (DPN) hastalarında CRP ve düşük yoğunluklu lipoprotein-kolesterol (LDL-K) düzeylerinin istatistiksel olarak anlamlı derecede yüksek olduğu görüldü. Gruplar arasında UA, GGT, CRP ve fibrinojen düzeyleri açısından istatistiksel olarak anlamlı bulunmadı.
Sonuç: Nöropatik ağrılı DPN hastalarında artmış CRP seviyeleri, DPN ile ilişkili ağrı patogenezinde yer alan inflamatuar mekanizmaları yansıtabilir.

Anahtar Kelimeler: CRP, diabetes mellitus, diyabetik nöropatik ağrı, diyabetik periferik nöropati, ürik asit


Which Markers Playing a Role in Diabetic Polyneuropathy and Neuropathic Pain?

Abstract
Objective: In diabetes mellitus (DM) patients, in the development of neuropathy and pain, uric acid (UA), C-reactive protein (CRP), γ-glutamyltransferase (GGT), erythrocyte sedimentation rate (ESR), and fibrinogen increased levels may play a role in the development of neuropathy by increasing oxidative stress through mechanisms related to inflammation and vascular damage. In this study, we aimed to compare serum UA, GGT, CRP, ESR, and fibrinogen levels in type 2 DM patients, with and without polyneuropathy (PNP).
Materials and Methods: Ninety-six patients with type 2 DM and twenty-four subjects as a control group were included in the study. Physical examinations, neuropathic pain scales, laboratory tests (UA, GGT, CRP, ESR, and fibrinogen levels), and electroneuromyography (ENMG) were evaluated.
Results: Ninety-six type 2 DM patients and twenty-four healthy individuals were included in the study as the control group. Diabetic polyneuropathy (DPN) patients with neuropathic pain showed that CRP and low-density lipoprotein cholesterol (LDL-C) levels were statistically significantly higher. Statistical significance was not found between the groups in terms of UA, GGT, CRP, and fibrinogen levels.
Conclusion: Increased CRP levels in DPN patients with neuropathic pain may reflect the inflammatory mechanisms involved in the pathogenesis of pain associated with DPN.

Key Words: CRP, diabetes mellitus, diabetic neuropathic pain, diabetic peripheral neuropathy, uric acid

Key words: Anahtar Kelimeler: CRP, diabetes mellitus, diyabetik nöropatik ağrı, diyabetik periferik nöropati, ürik asit Key Words: CRP, diabetes mellitus, diabetic neuropathic pain, diabetic peripheral neuropathy, uric acid






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.